176 related articles for article (PubMed ID: 33768560)
1. Association between interleukin 28B polymorphism and sustained virological response to sofosbuvir plus daclatasvir in chronic hepatitis C genotype 4 Egyptian patients.
Hassanien KS; El-Sayed EM; Ismail RS; Zakarya ZM; Helal GK
J Clin Pharm Ther; 2021 Aug; 46(4):942-949. PubMed ID: 33768560
[TBL] [Abstract][Full Text] [Related]
2. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection.
Sulkowski MS; Gardiner DF; Rodriguez-Torres M; Reddy KR; Hassanein T; Jacobson I; Lawitz E; Lok AS; Hinestrosa F; Thuluvath PJ; Schwartz H; Nelson DR; Everson GT; Eley T; Wind-Rotolo M; Huang SP; Gao M; Hernandez D; McPhee F; Sherman D; Hindes R; Symonds W; Pasquinelli C; Grasela DM;
N Engl J Med; 2014 Jan; 370(3):211-21. PubMed ID: 24428467
[TBL] [Abstract][Full Text] [Related]
3. Direct-acting antiviral agents in the treatment of chronic hepatitis C-Real-life experience from clinical practices in Pakistan.
Mushtaq S; Mansoor A; Umar M; Khan A; Siddiqi S; Manzoor S
J Med Virol; 2020 Dec; 92(12):3475-3487. PubMed ID: 32129507
[TBL] [Abstract][Full Text] [Related]
4. Polymorphism in interferon λ3/interleukin-28B gene and risk to noncirrhotic chronic hepatitis C genotype 3 virus infection and its effect on the response to combined daclatasvir and sofosbuvir therapy.
Khan AJ; Saraswat VA; Ranjan P; Parmar D; Negi TS; Mohindra S
J Med Virol; 2019 Apr; 91(4):659-667. PubMed ID: 30431653
[TBL] [Abstract][Full Text] [Related]
5. High Efficacy and Safety of Flat-Dose Ribavirin Plus Sofosbuvir/Daclatasvir in Genotype 3 Cirrhotic Patients.
Pellicelli A; Messina V; Giannelli V; Distefano M; Palitti VP; Vignally P; Tarquini P; Izzi A; Moretti A; Babudieri S; Dell'Isola S; Marignani M; Scifo G; Iovinella V; Cariti G; Pompili M; Candilo FD; Fontanella L; Ettorre GM; Vennarecci G; Ippolito AM; Barbarini G
Gut Liver; 2020 May; 14(3):357-367. PubMed ID: 30970444
[TBL] [Abstract][Full Text] [Related]
6. Response Tailored Protocol Versus the Fixed 12Weeks Course of Dual Sofosbuvir/Daclatasvir Treatment in Egyptian Patients With Chronic Hepatitis C Genotype-4 Infection: A Randomized, Open-label, Non-inferiority Trial.
Yakoot M; Abdo AM; Abdel-Rehim S; Helmy S
EBioMedicine; 2017 Jul; 21():182-187. PubMed ID: 28647541
[TBL] [Abstract][Full Text] [Related]
7. Daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a French early access programme.
Hézode C; Lebray P; De Ledinghen V; Zoulim F; Di Martino V; Boyer N; Larrey D; Botta-Fridlund D; Silvain C; Fontaine H; D'Alteroche L; Leroy V; Bourliere M; Hubert-Fouchard I; Guyader D; Rosa I; Nguyen-Khac E; Fedchuk L; Akremi R; Bennai Y; Filipovics A; Zhao Y; Bronowicki JP
Liver Int; 2017 Sep; 37(9):1314-1324. PubMed ID: 28177199
[TBL] [Abstract][Full Text] [Related]
8. Sofosbuvir-/Daclatasvir-based therapy for chronic HCV and HCV/hepatitis B virus coinfected patients in Egypt.
Nagaty A; Helmy SH; Abd El-Wahab EW
Trans R Soc Trop Med Hyg; 2020 Feb; 114(3):200-212. PubMed ID: 31722032
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and safety of daclatasvir/sofosbuvir with or without ribavirin in genotype 3 hepatitis C virus infected patients. Results in real clinical practice.
Margusino-Framiñán L; Cid-Silva P; Mena-de-Cea A; Rodríguez-Osorio I; Pernas-Souto B; Delgado-Blanco M; Pertega-Díaz S; Martín-Herranz I; Castro-Iglesias A
Rev Esp Quimioter; 2019 Apr; 32(2):137-144. PubMed ID: 30761823
[TBL] [Abstract][Full Text] [Related]
10. Predictive Potential Of Il28b Gene In Hcv Patients, Resistant To Daclatasvir And Sofosbuvir In KPK Population.
Sardar S; Muhammad S; Haq M; Haq NU; Kashif Khan AM
J Ayub Med Coll Abbottabad; 2023; 35(4):523-529. PubMed ID: 38406928
[TBL] [Abstract][Full Text] [Related]
11. Treatment of hepatitis C virus infection with direct-acting antivirals plus ribavirin eliminates viral RNA from peripheral blood mononuclear cells and reduces virologic relapse in diverse hepatic parenchymal changes.
Abd Alla MDA; Dawood RM; Rashed HAE; Farrag G; Ammar IAE; Mahmoud MMA; Salum GM; Altanbouly AMA; El Meguid MA; Awady MKE
Arch Virol; 2021 Apr; 166(4):1071-1081. PubMed ID: 33533976
[TBL] [Abstract][Full Text] [Related]
12. Real-world effectiveness and safety of sofosbuvir and nonstructural protein 5A inhibitors for chronic hepatitis C genotype 1, 2, 3, 4, or 6: a multicentre cohort study.
Charatcharoenwitthaya P; Wongpaitoon V; Komolmit P; Sukeepaisarnjaroen W; Tangkijvanich P; Piratvisuth T; Sanpajit T; Sutthivana C; Bunchorntavakul C; Sobhonslidsuk A; Chonprasertsuk S; Siripipattanamongkol C; Sethasine S; Tanwandee T;
BMC Gastroenterol; 2020 Mar; 20(1):47. PubMed ID: 32138687
[TBL] [Abstract][Full Text] [Related]
13. Sofosbuvir-based therapies in genotype 2 hepatitis C virus cirrhosis: A real-life experience with focus on ribavirin dose.
Smirne C; D'Avolio A; Bellan M; Gualerzi A; Crobu MG; Pirisi M
Pharmacol Res Perspect; 2021 Aug; 9(4):e00811. PubMed ID: 34152088
[TBL] [Abstract][Full Text] [Related]
14. Comparative efficacy of sofosbuvir-ribavirin versus sofosbuvir-daclatasvir for treatment of chronic hepatitis C in an area with limited NS5A inhibitor availability.
Kurniawan J; Gani RA; Hasan I; Sulaiman AS; Lesmana CRA; Jasirwan COM; Kalista KF; Nababan SHH; Zulkifly S
Indian J Gastroenterol; 2018 Nov; 37(6):520-525. PubMed ID: 30637537
[TBL] [Abstract][Full Text] [Related]
15. Ledipasvir/Sofosbuvir versus Daclatasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C Genotype 4 Patients.
Abdelaty LN; Elnaggar AA; Said AA; Hussein RRS
Curr Drug Saf; 2020; 15(1):53-60. PubMed ID: 31573893
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of Glycated Haemoglobin (HbA1c) Level in Type 2 Diabetic Chronic HCV Non-cirrhotic Treatment-Naïve Egyptian Patients Eradicated with Sofosbuvir Plus Daclatasvir.
Hussein HA; Allam AS; Moaty ASA
Curr Diabetes Rev; 2020; 16(2):165-170. PubMed ID: 31146663
[TBL] [Abstract][Full Text] [Related]
17. Baseline resistance associated substitutions in HCV genotype 1 infected cohort treated with Simeprevir, Daclatasvir and Sofosbuvir in Brazil.
Aguiar BF; Campos GRF; Rodrigues JPV; Marques NN; Molina BF; Bittar C; Souza FF; Martinelli ALC; Rahal P; Pereira LRL
Clin Res Hepatol Gastroenterol; 2020 Jun; 44(3):329-339. PubMed ID: 31523019
[TBL] [Abstract][Full Text] [Related]
18. Sofosbuvir-Containing Regimens for Chronic Hepatitis C Are Successful in the Safety-Net Population: A Real-World Experience.
Beck KR; Kim N; Khalili M
Dig Dis Sci; 2016 Dec; 61(12):3602-3608. PubMed ID: 27743164
[TBL] [Abstract][Full Text] [Related]
19. Value of IFNL3 genetic polymorphism in the prediction of HCV treatment response to direct-acting antiviral drugs versus interferon therapy.
Ghanem SE; Elsabaawy M; Shebl N; Abdelsameea E; Othman W; El-Bassal FI; Elgedawy GA; Elsabaawy DM; Helal ML
Expert Rev Anti Infect Ther; 2020 Sep; 18(9):947-954. PubMed ID: 32419526
[No Abstract] [Full Text] [Related]
20. Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients.
Pol S; Bourliere M; Lucier S; Hezode C; Dorival C; Larrey D; Bronowicki JP; Ledinghen VD; Zoulim F; Tran A; Metivier S; Zarski JP; Samuel D; Guyader D; Marcellin P; Minello A; Alric L; Thabut D; Chazouilleres O; Riachi G; Bourcier V; Mathurin P; Loustaud-Ratti V; D'Alteroche L; Fouchard-Hubert I; Habersetzer F; Causse X; Geist C; Rosa I; Gournay J; Saillard E; Billaud E; Petrov-Sanchez V; Diallo A; Fontaine H; Carrat F;
J Hepatol; 2017 Jan; 66(1):39-47. PubMed ID: 27622858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
